Porcine Vaccines Market Research Report: by Type (Inactivated Vaccines, DNA Vaccines), by Disease Indication (Diarrhea, Swine Influenza), By End User - Global Forecast Till 2023
Porcine vaccines are drugs administered to swine for protecting them against deadly pathogens and virus strains. The vaccines contain an inactivated form of the virus which can prompt a response from the immunity system and protect it against future infections. The global Porcine Vaccines Market report compiled by Market Research Future (MRFR) contains the various developments of vaccines and the future prospects of the vaccines during the period of 2018 to 2023 (forecast period).
Market Scope
The global porcine vaccines market is touted to expand at 7.1% CAGR over the forecast period. Rising number of swine diseases is the primary driver of the market. African swine fever (ASF) is a recent outbreak which has spread throughout the European Union (EU) and Asia. Major drivers of the market include demand for porcine meat, rising number of biotechnology companies, rise in funding of vaccines by research and development institutes, and inflow of capital to the animal husbandry sector.
But the high storage cost of vaccines can hamper the market growth.
Segmentation
The global porcine vaccines market has been segmented into type, disease indication, and end user.
By type, the market has been segmented into live attenuated vaccines, inactivated vaccines, DNA vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. Toxoid vaccines are inactivated vaccines containing toxins whose genetic structure has been modified to assist in responding actively to threats of viruses.
On the basis of disease indication, the market has been segmented into Aujeszky's disease (AD), swine influenza, PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Porcine Circovirus Associated Disease (PCVAD), and others. PCVAD is a single strand virus which replaces autonomously in eukaryotic cells.
The market, by end user, has been divided into veterinary hospitals and hog production farm.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/7438
Regional Analysis
The global porcine vaccines market has been segmented, by region, into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas will dominate the market owing to high consumption of pig meat and incidence of swine diseases. The rise in contract farming and independent farming for pig cultivation can drive the regional market growth. According to the National Hog Farmer, close to 71.7 million pigs were cultivated in farms in 2016. The development of gelatin based vaccines to prevent the vaccine viruses from external climatic conditions.
Europe held the second position in the market owing to large volumes of consumption of pig meat and recent spate of pig diseases. Awareness created of swine diseases in the EU as well as prevention measures to cull infected wild boars and pigs can drive the regional porcine vaccines market growth.
APAC is predicted to deliver the fastest growth during the forecast period owing to the large population and cultivation of pigs for exports. China, Cambodia, Laos, Australia, and Japan are the biggest contributors of the region. Recombinant DNA vaccines are administered to piglets to induce immune responses in their systems. The expression of IL-18 and M proteins in the body can enhance the potency of the vaccines.
Lastly, the MEA region can account for the lowest share of the global porcine vaccines market owing to efforts taken by governments to promote betterment of animal health. Labeling of halal ingredients used in the vaccine and acceptance of antigens by religious leaders for its mass production can drive the market demand in the region.
Competitive Outlook
Merck & Co., Inc., Vetoquinol S.A., Boehringer Ingelheim International GmbH, Sanofi S.A., Ceva Sante Animale, Zoetis, Inc., Eli Lilly and Company, Aptimmune, Bimeda, Inc., Bayer AG, and PBS Animal Health are key players of the global porcine vaccines market.
Porcine vaccines are drugs administered to swine for protecting them against deadly pathogens and virus strains. The vaccines contain an inactivated form of the virus which can prompt a response from the immunity system and protect it against future infections. The global Porcine Vaccines Market report compiled by Market Research Future (MRFR) contains the various developments of vaccines and the future prospects of the vaccines during the period of 2018 to 2023 (forecast period).
Market Scope
The global porcine vaccines market is touted to expand at 7.1% CAGR over the forecast period. Rising number of swine diseases is the primary driver of the market. African swine fever (ASF) is a recent outbreak which has spread throughout the European Union (EU) and Asia. Major drivers of the market include demand for porcine meat, rising number of biotechnology companies, rise in funding of vaccines by research and development institutes, and inflow of capital to the animal husbandry sector.
But the high storage cost of vaccines can hamper the market growth.
Segmentation
The global porcine vaccines market has been segmented into type, disease indication, and end user.
By type, the market has been segmented into live attenuated vaccines, inactivated vaccines, DNA vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. Toxoid vaccines are inactivated vaccines containing toxins whose genetic structure has been modified to assist in responding actively to threats of viruses.
On the basis of disease indication, the market has been segmented into Aujeszky's disease (AD), swine influenza, PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Porcine Circovirus Associated Disease (PCVAD), and others. PCVAD is a single strand virus which replaces autonomously in eukaryotic cells.
The market, by end user, has been divided into veterinary hospitals and hog production farm.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/7438
Regional Analysis
The global porcine vaccines market has been segmented, by region, into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas will dominate the market owing to high consumption of pig meat and incidence of swine diseases. The rise in contract farming and independent farming for pig cultivation can drive the regional market growth. According to the National Hog Farmer, close to 71.7 million pigs were cultivated in farms in 2016. The development of gelatin based vaccines to prevent the vaccine viruses from external climatic conditions.
Europe held the second position in the market owing to large volumes of consumption of pig meat and recent spate of pig diseases. Awareness created of swine diseases in the EU as well as prevention measures to cull infected wild boars and pigs can drive the regional porcine vaccines market growth.
APAC is predicted to deliver the fastest growth during the forecast period owing to the large population and cultivation of pigs for exports. China, Cambodia, Laos, Australia, and Japan are the biggest contributors of the region. Recombinant DNA vaccines are administered to piglets to induce immune responses in their systems. The expression of IL-18 and M proteins in the body can enhance the potency of the vaccines.
Lastly, the MEA region can account for the lowest share of the global porcine vaccines market owing to efforts taken by governments to promote betterment of animal health. Labeling of halal ingredients used in the vaccine and acceptance of antigens by religious leaders for its mass production can drive the market demand in the region.
Competitive Outlook
Merck & Co., Inc., Vetoquinol S.A., Boehringer Ingelheim International GmbH, Sanofi S.A., Ceva Sante Animale, Zoetis, Inc., Eli Lilly and Company, Aptimmune, Bimeda, Inc., Bayer AG, and PBS Animal Health are key players of the global porcine vaccines market.
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid-19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
No comments:
Post a Comment